<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/co.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
    <script type="text/javascript" charset="utf-8">
		

		ANIMATION = [
				fade('.yellowbk'),
				fade('#panel1'),
				fade('#panel2')
		   ];
		
	</script>
    
    <script type="text/javascript">
			
			
		function touching() {
			var touchBtn = document.getElementById("touch");
			var panel1 = document.getElementById("panel1");
			var panel2 = document.getElementById("panel2");
			
			if (panel1.className!='active') {
				panel1.setAttribute('class','active');
			}else {
				panel2.setAttribute('class','active');
			}
			
			};
	</script>
    

</head>

<body class="slide-2">

<div id="content">
<div class="collage"></div>

<header style="top:18px;">
The convenience of QD dosing

</header>

<div class="logo"></div>

<section onclick="touching()">

<div class="yellowbk">
	<div class="chartbk" >
    

			
                <div id="panel1">

                    <div class="copy1">KALETRA 800 mg/200 mg <br>(four 200-mg/50-mg tablets) once<br>daily with or without food, taken<br>whole, not chewed or crushed.</div>
					<div class="copy2"><img src="images/co-02-pills.jpg" width="336" height="61"></div>
                    
                
                
                </div>
            
            
            
			<div id="panel2">
            

                	
                    <div id="greenback"></div>
                    <div id="or"><img src="images/co-02-or.png" width="82" height="76"></div>
                    <div id="bluepill"><img src="images/co-02-bluepill.jpg" width="84" height="46" alt="Blue Pill"></div>
                	<div class="copy3">May be used in <br>combination with one<br>TRUVADA<sup>®</sup> tablet*<br>once daily with or <br>without food</div>

            
            </div>
    
    
    </div></div>
    <div class="disc">Tablets shown are not actual size or color.<br>KALETRA is not specifically indicated to be used in combination with TRUVADA. TDF concentrations have been shown to increase when used in combination with KALETRA; monitor patient for adverse reactions associated with tenofovir. Please see the TRUVADA Full Prescribing Information for full Indication and Important Safety Information.</div>
    <div class="disc2">*TRUVADA<sup>®</sup> [emtricitabine/tenofovir disoproxil fumarate (TDF)] is a registered trademark of Gilead Sciences, Inc.</div>
   
   <div class="safety" style="width:1000px;">
    <p><strong>Safety Considerations</strong></p>
	<p class="bullet">Do not administer once-daily KALETRA in adult patients with three or more lopinavir resistance-associated substitutions.</p>
    <p class="bullet">KALETRA should not be administered once daily in combination with efavirenz, nevirapine, nelfinavir, carbamazepine, <br/>phenobarbital, or phenytoin.</p>
    <p class="bullet">KALETRA tablets should not be administered once daily in pediatric patients &lt;18 years of age.</p>
    <p class="bullet">Patients should be informed that there may be a greater chance of developing <br>diarrhea with the once-daily regimen as compared with the twice-daily regimen.</p>
        
    
    </div>
    


</section>



<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>


</div>
</body>
</html>